Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · H2 FY26

Evoq Remedies H2 FY26 Results: Net Loss of ₹0.3 Cr

Evoq Remedies Ltd reported a net loss of ₹0.3 Cr for H2 FY26.

H2 FY26 at a glance · ₹ crore
MetricH2 FY26H1 FY26H2 FY25
Revenue from operations0.025.511.8
Other income0.21.12.4
Total income0.226.614.2
Profit before exceptional items & tax-0.30.11.8
Profit before tax-0.30.11.8
Net profit-0.30.11.7
Operating margin-150.0%0.4%12.7%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Source

BSE results filing, BSE: 543500. Figures extracted from the filing.

Read the filing ↗

Evoq Remedies Ltd: key numbers

Share price
₹1.54
Market cap
₹3.83 Cr
Revenue (annual)
₹25.51 Cr
Net profit (annual)
₹-0.24 Cr
P/E (TTM)
-16.0×Sector 53.1×
Promoter holding
0.02%
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Evoq Remedies Ltd

All →
17:15 IST BSE
Insolvency Petition

Evoq Remedies Insolvency Petition

NCLT admitted CIRP against Evoq Remedies Ltd for a Rs.1.95 Crore operational debt. An IRP has been appointed, and a moratorium is in effect.

Value
₹1.95 Cr
18:11 IST BSE
Insolvency Petition

Evoq Remedies Insolvency Petition

An operational creditor has filed an insolvency petition against Evoq Remedies under IBC Section 9. The NCLT admission initiates the CIRP process, posing significant risk for shareholders.

19:44 IST BSE
Financial Results

Evoq Remedies Financial Results

Evoq Remedies Limited reported audited financial results for the year ended March 31, 2026. The auditor issued a qualified opinion citing material uncertainty regarding going concern.

19:33 IST BSE
Financial Results

Evoq Remedies Financial Results

Evoq Remedies Limited reported annual revenue of ₹26.76 Crore for FY2026. The board also appointed M/s. Jay Pandya & Associates as secretarial auditors for FY2025-26.

Value
₹26.76 Cr
12:42 IST BSE
Board Meeting Date

Evoq Remedies Board Meeting Date

Evoq Remedies rescheduled its board meeting from May 27 to May 30, 2026. Directors will consider audited financial results for the fiscal year ended March 31.

18:17 IST BSE
Board Meeting Date

Evoq Remedies Board Meeting Date

Evoq Remedies rescheduled its Board Meeting from May 14 to May 27, 2026. Directors will consider audited financial results for the fiscal year ended March 2026.